307 related articles for article (PubMed ID: 34236120)
21. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
22. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
[TBL] [Abstract][Full Text] [Related]
24. Based on Gadolinium Ethoxybenzyl DTPA-Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma.
Li S; Deng K; Qiu J; Wang P; Yin D; Xie Y; Yu Y
Technol Cancer Res Treat; 2024; 23():15330338241256859. PubMed ID: 38780516
[No Abstract] [Full Text] [Related]
25. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
26. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
[TBL] [Abstract][Full Text] [Related]
27. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
Yao S; Wei Y; Ye Z; Chen J; Duan T; Zhang Z; Song B
J Magn Reson Imaging; 2024 Jun; 59(6):2060-2070. PubMed ID: 34121266
[TBL] [Abstract][Full Text] [Related]
28. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System.
Yang J; Jiang H; Xie K; Bashir MR; Wan H; Huang J; Qin Y; Chen J; Lu Q; Song B
Eur J Radiol; 2022 Sep; 154():110397. PubMed ID: 35696735
[TBL] [Abstract][Full Text] [Related]
29. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
[TBL] [Abstract][Full Text] [Related]
30. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
[TBL] [Abstract][Full Text] [Related]
31. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
[No Abstract] [Full Text] [Related]
33. The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
Pan J; Song M; Yang L; Zhao Y; Zhu Y; Wang M; Chen F
Eur Radiol; 2023 Aug; 33(8):5801-5811. PubMed ID: 36894754
[TBL] [Abstract][Full Text] [Related]
34. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
[TBL] [Abstract][Full Text] [Related]
35. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
[TBL] [Abstract][Full Text] [Related]
36. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.
Choi SH; Byun JH; Kim SY; Lee SJ; Won HJ; Shin YM; Kim PN
Invest Radiol; 2016 Aug; 51(8):483-90. PubMed ID: 26885632
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
[TBL] [Abstract][Full Text] [Related]
38. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
[TBL] [Abstract][Full Text] [Related]
39. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.
Lee S; Kim YY; Shin J; Roh YH; Choi JY; Chernyak V; Sirlin CB
Eur Radiol; 2024 Mar; 34(3):1502-1514. PubMed ID: 37656177
[TBL] [Abstract][Full Text] [Related]
40. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?
Zhang N; Xu H; Ren AH; Zhang Q; Yang DW; Ba T; Wang ZC; Yang ZH
J Magn Reson Imaging; 2021 Dec; 54(6):1922-1934. PubMed ID: 33963801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]